How Does Allergy Desensitization Work? Every Immunotherapy Form Explained

Antihistamines block histamine receptors after the allergic cascade has already been triggered — they reduce symptoms but do not alter the underlying immune process that causes them. Desensitization (immunotherapy) intervenes at a much earlier step: it prevents the allergic cascade from being triggered in the first place by retraining the immune system to tolerate the allergen. Antihistamines stop working when you stop taking them because the immune mechanism is unchanged. Desensitization produces lasting immune change that persists for years after stopping treatment in most patients. The difference is analogous to treating pain versus healing the underlying injury — both help, but only one produces durable change.

Sublingual immunotherapy (SLIT) — both drops and tablets — has the best safety profile of any desensitization modality for aeroallergens. A pediatric network meta-analysis (Wang et al., Front Pharmacol 2024) found SLIT had 83% fewer treatment-related adverse events than SCIT. No confirmed fatalities have been documented with SLIT tablets across large FDA-review datasets. SCIT carries a systemic reaction rate of approximately 0.1% per injection and a historical fatality rate of about 1 per 2.5 million injections, currently running approximately 0.8 fatalities per year in the US. SCIT's safety risk is manageable — it is why the 30-minute post-injection observation is mandatory — but SLIT is genuinely and substantially safer for equivalent efficacy in approved allergens.

No desensitization treatment currently achieves a guaranteed permanent cure — all modalities induce clinical tolerance rather than irreversible immune reset. However, SCIT and SLIT can produce sustained clinical remission lasting 3 to 12 years after a 3- to 5-year course in most patients. VIT after 5 years allows most patients to discontinue with maintained protection. OIT typically requires ongoing maintenance dosing because it produces desensitization (temporary protection) rather than sustained unresponsiveness. The best available evidence for the most durable disease modification comes from SCIT and SLIT, where regulatory T-cell memory can sustain tolerance long after treatment ends.

Intralymphatic immunotherapy (ILIT) is an investigational approach that delivers allergen directly into inguinal lymph nodes via ultrasound-guided injection. The rationale is that targeting allergen presentation directly to lymph nodes — where T-cell education occurs — could achieve tolerance with dramatically fewer doses. Senti et al. (PNAS 2008) demonstrated that just 3 ILIT injections over 8 weeks produced immunological changes comparable to 54 conventional SCIT injections in grass-allergic patients, with sustained clinical benefit at 3-year follow-up. However, ILIT is not FDA-approved, remains investigational, and requires specialized centers with ultrasound guidance. Further phase III trials are needed before it becomes a standard clinical option.

Oral immunotherapy (OIT) uses the same graduated allergen exposure principle as aeroallergen desensitization but delivers allergen by ingestion rather than injection or sublingual absorption. For peanut allergy, Palforzia (FDA-approved 2020) uses escalating daily oral doses of peanut flour protein, starting at 0.5 mg and escalating to 300 mg maintenance. The PALISADE trial showed 67% of OIT-treated patients tolerated 600 mg peanut protein (about 2 peanuts) versus 4% of placebo patients. Key difference from SCIT and SLIT: most OIT patients require indefinite ongoing maintenance dosing — stopping OIT often results in relapse because sustained unresponsiveness (true tolerance) is less commonly achieved than with aeroallergen SCIT. OIT also carries higher systemic reaction rates than SLIT.

Epicutaneous immunotherapy (EPIT), delivered through an allergen-impregnated skin patch (Viaskin), is currently investigational and not approved for clinical use. The Viaskin Peanut patch (DBV Technologies) delivers peanut allergen through intact skin to Langerhans cells in the epidermis, attempting to induce tolerance without systemic allergen exposure. Phase III trials for peanut EPIT showed modest desensitization benefits, particularly in children aged 4 to 7 years, but results were considered insufficient for FDA approval as of 2025. Research continues. For aeroallergens like grass and house dust mite, EPIT has shown promising early phase results but has not advanced to large phase III trials. EPIT is not currently available outside clinical trials.